Evidence Summary
- Evidence Level
- Preliminary
- Mechanism
- Enrollment: Estimated, Sponsor Type: Other, Unknown / General
- Safety
- Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
- Dosing
- See linked studies/trials for reported doses and durations; typical protocols vary widely.
Mount Sinai RCT recruiting (NCT06511050) for microclots in Long COVID/ME-CFS. Fibrinolytic. 20-40mg 2-3x/day protocols. Low bleeding risk but caution with anticoagulants. Rigorous trial underway; currently research-only.
Clinical Trials
1 trial(s) registered
| NCT ID | Title | Phase | Status |
|---|---|---|---|
| NCT06511050 | Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | Phase 1 | Recruiting |
Key Studies / References
- See linked studies